PROMENADE, a real-world French cohort from 12 cancer centers (n=114), suggested that ER/PR-low (1–9%) HER2– EBC patients achieved a 75% pCR rate with the KEYNOTE-522 regimen. The gene discussed is ERBB2; the disease is cancer.